About the Program
In 2002, Bayer HealthCare instituted the Bayer Hemophilia Awards Program with the following mission:
The Bayer Hemophilia Awards Program supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training, and other hemophilia care professionals, the program seeks to support the next steps for the next generation of care and treatment options for people with hemophilia worldwide.
Who We Are
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, with annual sales of EUR 16,913 million (2010), is one of the world’s leading, innovative companies in the health care and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53,400 employees and is represented in more than 100 countries.
Bayer envisions the Hemophilia Awards Program as a step toward making the dream of hemophilia cures and improved treatments a reality.
The Bayer Hemophilia Awards Program demonstrates our commitment to the global bleeding disorders community and to advancing the state of the art of hemophilia care.
The program’s research priorities for the 2018/2019 cycle are as follows:
Clinical Research Award
- Subclinical bleeds
- Joint pain
- Patient-reported outcomes
- Role of FVIII vs. non-FVIII replacement therapy
- Lab monitoring, etc.
Basic Research Award
- Role of FVIII outside of coagulation
- Lab monitoring research and applications.
In previous award cycles the Program has provided funding to support several projects in the following areas:
- Aspects of the molecular biology of vWF structure and function and the diagnosis and treatment of vWD
- The function and regulation of platelets and the diagnosis of platelet disorders.
As a result, the Program will not award projects in these areas during this award cycle.
Excluded Research Topics
In order to maintain a focus on hemophilia and bleeding disorders, the Program will not support research focused on:
- Products or technologies licensed or patented by competitors of Bayer
- Cancer diagnosis or therapy
- AIDS diagnosis or hepatitis therapy except where specifically related to patients with hemophilia and HIV, HCV or HBV
- Cardiovascular disease diagnosis or therapy
- Purely thrombotic disorders.
Dates & Deadlines
Thank you for your interest in applying for the Bayer Hemophilia Awards Program. This program represents Bayer’s continuing commitment to taking the next steps for the next generation of people with hemophilia to enjoy a better quality of life and treatment options.
Applications will be processed solely online and all applications must be submitted in English.
As a first step, applicants should submit a Letter of Intent (LOI) describing the proposed project in 500 words or fewer. People who submit LOIs will receive an email confirming receipt.
LOIs will be reviewed by all 10 members of the Grants Review and Awards Committee and, in some cases, additional information may be requested.
Selected applicants will be invited to submit a Full Proposal that will be reviewed by at least two members of the Grants Review and Awards Committee. These applicants will be emailed a Full Proposal application form.
The results of the review process and funding decisions for the 2019/2020 cycle will be communicated to applicants in April. Funded applicants must send a letter of acceptance and enter into an agreement outlining obligations and understandings prior to disbursement of funds.
Awardees will be invited to attend an Awards Dinner that will coincide with the biennial meetings of the World Federation of Hemophilia (WFH) or the International Society on Thrombosis and Haemostasis (ISTH).
The table below summarizes the application timelines for 2019/2020.
|LOI submissions||Permitted throughout the year|
|Deadline for LOI consideration||November 30, 2019|
|GRAC reviews LOIs||December 2019|
|GRAC informs applicants||January 2020|
|Applicants develop Full Proposals||January/February 2020|
|Full Proposals submitted||February 2020|
|GRAC reviews Full Proposals||March 2020|
|Applicants notified of GRAC decisions||April 2020|
|Funding available||July/August 2020|
Letters of Intent and Full Applications are reviewed by the Grants Review and Awards Committee which comprises 10 members, representing many of the leading experts from clinical and academic medicine:
- Alok Srivastava MD, Vellore, India (chairman)
- Valder Arruda MD, Philadelphia, USA
- Marijke van den Berg MD, Utrecht, Netherlands
- Craig Kessler MD, Washington DC, USA
- Riitta Lassila MD, Helsinki, Finland
- David Lillicrap MD, Kingston, Canada
- Pier Mannucci MD, Milan, Italy
- Johannes Oldenburg MD, Bonn, Germany
- Midori Shima MD, Nara, Japan
- Gil White MD, Milwaukee, WI, USA
All members of the Grants Review and Awards Committee will review the Letters of Intent and determine which candidates will be invited to submit full applications. Full applications will be reviewed by at least two members of the committee.
Reviewers will evaluate full applications according to the criteria outlined in the Awards section of this website. The reviewers will provide written comments and preliminary numeric scores according to these criteria.
The Committee will meet to discuss individual proposals including strengths, weaknesses and scoring. In this meeting, a consensus score for each grant application will be agreed upon. Proposals will then be ranked according to these scores in order to determine funding. In the event of identical scoring, the Committee will discuss the proposals in question and revise the scoring in order to clearly define a ranked priority. Funding will occur on a regional basis.
Three regions are defined as:
- United States and Canada
- Europe (for the purposes of this award, the Europe region includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom)
- Japan, China, India, Australia and all other countries.
Awards will be determined on the final priority score as agreed by the Grants Review and Awards Committee. In the event that inadequate numbers of acceptable applications are received from a particular region, additional acceptable proposals will be funded solely on the basis of priority scores, without regard to region.
The Committee’s decision is final and there is no appeal mechanism. Applicants who have constructive suggestions about the review of their applications, or the process in general, are encouraged to contact us. See Contact.
Conflict of Interest
The Program has ‘conflict of interest’ guidelines that ensure reviews are conducted in a fair and equitable manner. Reviewers will not participate in the review or priority scoring of applications in which they, or institutions with which they are affiliated, have an interest. Also, to the extent practicable, reviewers will not participate in the review of proposals competing for funding with proposals for individuals associated with their institutions.
The members of the Grants Review and Awards Committee are bound by the confidentiality rules generally applicable to such bodies.
Award Recipients: 2019
Fellowship Project Awards
Dr. Oliver Königsbrügge
Medical University of Vienna Department of Medicine I Clinical Division of Hematology and Hemostaseology, Austria
Laboratory measurements for monitoring the treatment of patients with hemophilia treated with FVIII-, FIX-replacement therapies and non-factor therapeutics
Basic Research Award
Dr. Radoslaw Kaczmarek
Indiana University, USA
Developing a novel approach of transcutaneous tolerance induction in hemophilia mice
Professor Christian Kastrup
University of British Columbia, Canada
Developing a Long-Acting Prophylactic Treatment for Hemophilia using siRNA Mediated Inhibition of Fibrinolysis
Dr. Shekhar Kumar
The Children’s Hospital of Philadelphia, USA
Structural Basis for Inhibition of Intrinsic Tenase Complex by Natural and Synthetic Ligands
Professor Sébastien Lacroix-Desmazes
INSERM DR Paris 6, France
Importance of FVIII-containing immune complexes on the induction of immune tolerance in hemophilia A
Dr. Maurizio Tomaiuolo
University of Pennsylvania, USA
Role of activated Protein C in hemostasis
Clinical Research Award
Dr. DMWM Te Loo
Radboudumc Center of Expertise Hemophilia Treatment Genter Department of Hematology, The Netherlands
The role of the genetic variance in the inflammatory profile of Hemophilia A patients related to joint damage